Mixed
Metabolic surgery significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality in patients with type 2 diabetes and obesity compared to usual care.
For patients with type 2 diabetes and obesity, metabolic surgery is associated with a significantly lower risk of major cardiovascular events and death compared to usual care. This includes reductions in heart failure, stroke, and mortality. While surgery carries short-term risks, the long-term cardiovascular benefits are substantial.
Among patients with type 2 diabetes and obesity, metabolic surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident MACE.
Why this rating
Large retrospective cohort study with propensity matching, but explicitly acknowledged as observational and requiring confirmation in RCTs.
Source
Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity
Ali Aminian et al. · JAMA · 2019
DOI 10.1001/jama.2019.14231
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →